Dustin S. Sjuts
Net Worth
Last updated:
What is Dustin S. Sjuts net worth?
The estimated net worth of Mr. Dustin S. Sjuts is at least $3,341,789 as of 9 Jun 2023. He owns shares worth $537,817 as insider, has earned $1,559,452 from insider trading and has received compensation worth at least $1,244,520 in Revance Therapeutics, Inc..
What is the salary of Dustin S. Sjuts?
Mr. Dustin S. Sjuts salary is $622,260 per year as Pres in Revance Therapeutics, Inc..
How old is Dustin S. Sjuts?
Mr. Dustin S. Sjuts is 46 years old, born in 1979.
What stocks does Dustin S. Sjuts currently own?
As insider, Mr. Dustin S. Sjuts owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Revance Therapeutics, Inc. (RVNC) | Pres | 147,347 | $3.65 | $537,817 |
What does Revance Therapeutics, Inc. do?
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Dustin S. Sjuts insider trading
Revance Therapeutics, Inc.
Mr. Dustin S. Sjuts has made 3 insider trades in 2023, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of RVNC stock worth $154,095 on 9 Jun 2023.
The largest trade he's ever made was exercising 21,508 units of RVNC stock on 9 Mar 2023. As of 9 Jun 2023 he still owns at least 147,347 units of RVNC stock.
Revance Therapeutics key executives
Revance Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Abhay Joshi (62) Chief Operating Officer, Pres of R&D and Product Operations
- Mr. Dustin S. Sjuts (46) Pres
- Mr. Dwight Moxie (48) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Mark J. Foley (60) Chief Executive Officer & Director
- Mr. Tobin C. Schilke (50) Chief Financial Officer & Principal Accounting Officer